Please login to the form below

Not currently logged in
Email:
Password:

delamanid

This page shows the latest delamanid news and features for those working in and with pharma, biotech and healthcare.

Study shows Otsuka's TB drug works even in worst cases

Study shows Otsuka's TB drug works even in worst cases

The analysis of data from phase IIb trials of Deltyba (delamanid) reveals that the drug can be effective even in cases of TB that are unlikely to respond to any other ... More new medicines are urgently needed to prevent XDR-TB from becoming a death

Latest news

  • R&D productivity takes off R&D productivity takes off

    Other first-in-class agents include: Merck &Co's PAR-1 antagonist Zontivity (vorapaxar), a novel antiplatelet agent; AstraZeneca's PARP inhibitor Lynparza (olaparib) for cancer; Otsuka's Deltyba (delamanid), a

  • Otsuka wins approval for TB drug Deltyba Otsuka wins approval for TB drug Deltyba

    This week the European Commission granted the Japanese firm authorisation to market Deltyba (delamanid) almost two months after backing Johnson &Johnson's Sirturo (bedaquiline) in a similar indication. ... was “too short to establish the effectiveness

  • Tuberculosis: treatment and prevention Tuberculosis: treatment and prevention

    Otsuka Pharmaceutical is developing delamanid, a nitro-dihydroimidazo-oxazole derivative, for use as an oral anti-TB agent. ... Delamanid is also in phase 3 development in the US, Estonia, India, Latvia, Lithuania, Moldova, Peru, South Africa and the

  • J&J gets EU green light for novel TB drug J&J gets EU green light for novel TB drug

    delamanid), which was given a conditional approval last November along with Lucane Pharma SA's para-aminosalicylic acid.

  • Cell wall inhibitors for bacterial infections Cell wall inhibitors for bacterial infections

    The nitro-dihydroimidazo-oxazole derivative Delamanid (Deltyba; Otsuka Pharmaceutical) inhibits mycolic acid synthesis and thus the formation of the mycobacterial cell envelope.

More from news
Approximately 4 fully matching, plus 6 partially matching documents found.

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
SEVEN STONES

Seven Stones is a creative, independent healthcare communications agency of movers and thinkers. We've been doing health differently since 1991....

Latest intelligence

InSite Events™ National Pharma Meeting: A Customer Story
How our client leveraged Impetus Digital’s white-glove service, 360° coverage and care, and award-winning InSite Events™ platform to successfully transfer their annual national meeting online....
Fear or encouragement, which is best to drive behaviour change?
The communications industry depends on fear of the perceived loss of something, in order to create the hope found in a product benefit. But, if if left too long unchecked,...
The unheard, unseen, and uncorrected effects of COVID-19
The disproportionate effects of the pandemic have been highlighted amongst ethnic minorities, so is it likely that ethnic minorities will be more worried about participating? And could this exacerbate inequalities...

Infographics